Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects

Thymoxamine, a prodrug, is rapidly deacetylated in the plasma to give two phase I metabolites, DMAT and DAT, which are further sulpho- and glucuro-conjugated and then excreted mainly in the urine. In a cross-over study, the dose-dependence of the metabolite ratio was evaluated in nine healthy volunt...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of drug metabolism and pharmacokinetics Vol. 16; no. 3; p. 183
Main Authors Marquer, C, Trouvin, J H, Lacolle, J Y, Dupont, C, Jacquot, C
Format Journal Article
LanguageEnglish
Published France 01.07.1991
Subjects
Adult
Dose-Response Relationship, Drug
Humans
Male
Moxisylyte - administration & dosage
Moxisylyte - analogs & derivatives
Moxisylyte - blood
Moxisylyte - pharmacokinetics
Prodrugs - administration & dosage
Prodrugs - pharmacokinetics
Random Allocation
Online AccessGet more information

Cover

More Information
Summary:Thymoxamine, a prodrug, is rapidly deacetylated in the plasma to give two phase I metabolites, DMAT and DAT, which are further sulpho- and glucuro-conjugated and then excreted mainly in the urine. In a cross-over study, the dose-dependence of the metabolite ratio was evaluated in nine healthy volunteers after three doses (120, 240, 480 mg) of thymoxamine-HCl. Regardless of the dose, DMAT and its glucuronide were not detected, while the amount of DMAT-sulphate was found to be proportional to the dose administered. Plasma levels of DAT were measurable in only four of the nine subjects after the 480 mg dose and showed great intersubject variability. The pharmacokinetics of both DAT-sulphate and DAT-glucuronide were dose-dependent. As the dose increased, the proportion of DAT undergoing sulphatation decreased; this saturation was compensated by glucuronidation.
ISSN:0378-7966
DOI:10.1007/BF03189957